Iovance Biotherapeutics Inc. — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

4 Recruiting

4 Completed trials

16 Countries active

16 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 1 Phase II: 7 Phase I: 1

Oversight events:

13 temporary halts 2 unexpected events 1 corrective measure across 2 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute lymphocytic leukaemia refractory 1 Non-small cell lung cancer 1 Malignant melanoma 1 BRAF V600E mutation positive 1 BRAF gene mutation 1 Squamous cell carcinoma of head and neck 1

Top IMPs

CYCLOPHOSPHAMIDE 4 ALDESLEUKIN 3 AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES 3 FLUDARABINE PHOSPHATE 3 LIFILEUCEL 3 CYCLOPHOSPHAMIDE MONOHYDRATE 2 PEMBROLIZUMAB 2 (3R)-N-[3-[5-(2-CYCLOPROPYLPYRIMIDIN-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUOROPHENYL]-3-FLUOROPYRROLIDINE-1-SULFONAMIDE 1 COBICISTAT 1 HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE 1 LTG-001 1

All trials

9 total

An efficacy and safety study of LTG-001 in osteoarthritis Pending

2025-522755-26-01 Phase II 1 country LTG-001
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Phase III 12 countries ALDESLEUKIN; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE MONOHYDRATE; FLUDARABINE PHOSPHA…
A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Phase II 6 countries ALDESLEUKIN; AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES; CYCLOPHOSPHAMIDE; CYCLO…
SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study Recruiting

2025-521560-36-00 Phase II 11 countries HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan… Recruiting

2024-513578-23-00 Phase II 7 countries (3R)-N-[3-[5-(2-CYCLOPROPYLPYRIMIDIN-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]…
A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back aft… Ended

2023-509132-26-00 Phase I 2 countries
A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a… Ended

2024-510779-39-00 Phase II 3 countries AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPH…
A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat… Ended

2024-510634-41-00 Phase II 5 countries AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended

2025-522054-40-00 Phase II 4 countries ALDESLEUKIN; CYCLOPHOSPHAMIDE; LIFILEUCEL

Showing 1–9 of 9 trials

← All sponsors A–Z